HK1213777A1 - 在胰岛移植中作为佐剂的cxcr1/2抑制剂 - Google Patents

在胰岛移植中作为佐剂的cxcr1/2抑制剂 Download PDF

Info

Publication number
HK1213777A1
HK1213777A1 HK16101720.7A HK16101720A HK1213777A1 HK 1213777 A1 HK1213777 A1 HK 1213777A1 HK 16101720 A HK16101720 A HK 16101720A HK 1213777 A1 HK1213777 A1 HK 1213777A1
Authority
HK
Hong Kong
Prior art keywords
transplantation
mice
islet
raparicin
cxcr1
Prior art date
Application number
HK16101720.7A
Other languages
English (en)
Chinese (zh)
Inventor
洛倫佐．皮耶蒙蒂
洛伦佐．皮耶蒙蒂
路易莎．達豐希奧
路易莎．达丰希奥
馬爾塞洛．阿萊格雷蒂
马尔塞洛．阿莱格雷蒂
Original Assignee
多姆皮制药公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 多姆皮制药公司 filed Critical 多姆皮制药公司
Publication of HK1213777A1 publication Critical patent/HK1213777A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK16101720.7A 2009-10-06 2016-02-18 在胰岛移植中作为佐剂的cxcr1/2抑制剂 HK1213777A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172364A EP2308484A1 (en) 2009-10-06 2009-10-06 Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP09172364.3 2009-10-06

Publications (1)

Publication Number Publication Date
HK1213777A1 true HK1213777A1 (zh) 2016-07-15

Family

ID=41818891

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101720.7A HK1213777A1 (zh) 2009-10-06 2016-02-18 在胰岛移植中作为佐剂的cxcr1/2抑制剂

Country Status (24)

Country Link
US (1) US20120202884A1 (enExample)
EP (2) EP2308484A1 (enExample)
JP (2) JP5834010B2 (enExample)
KR (2) KR101817912B1 (enExample)
CN (2) CN104906572A (enExample)
AU (1) AU2010305385B2 (enExample)
BR (1) BR112012007991B8 (enExample)
CA (1) CA2775902C (enExample)
CY (1) CY1115018T1 (enExample)
DK (1) DK2485723T3 (enExample)
EA (1) EA021298B1 (enExample)
ES (1) ES2451349T3 (enExample)
HK (1) HK1213777A1 (enExample)
HR (1) HRP20140202T1 (enExample)
IL (1) IL219037A (enExample)
ME (1) ME01719B (enExample)
MX (1) MX2012004082A (enExample)
NZ (1) NZ599172A (enExample)
PL (1) PL2485723T3 (enExample)
PT (1) PT2485723E (enExample)
RS (1) RS53249B (enExample)
SI (1) SI2485723T1 (enExample)
SM (1) SMT201400033B (enExample)
WO (1) WO2011042466A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
CN103159652B (zh) * 2011-12-19 2016-06-08 天津市国际生物医药联合研究院 亚磺酰胺类化合物的制备及其应用
CN105722972A (zh) 2013-06-18 2016-06-29 纽约大学 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素：新型治疗靶点
CN109890364B (zh) 2016-10-03 2023-10-17 儿童医疗中心公司 糖尿病肾病的预防和治疗

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
US20020042370A1 (en) * 2000-04-14 2002-04-11 Millennium Pharmaceuticals, Inc. Method of treating graft rejection using inhibitors of CCR2 function
WO2001078708A1 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Treating graft rejection with cxcr3 inhibitors
ITMI20010206A1 (it) 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PT1776336E (pt) * 2004-03-23 2009-12-18 Dompe Spa Derivados de ácido 2-fenilpropiónico e composições farmacêuticas que os contêm
EP1579859B1 (en) 2004-03-25 2006-12-13 DOMPE' pha.r.ma s.p.a. Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury
US20050261762A1 (en) * 2004-05-21 2005-11-24 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
TWI400232B (zh) * 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
JP5232144B2 (ja) * 2006-06-28 2013-07-10 サノフイ Ｃｘｃｒ２阻害剤
JP2010504996A (ja) * 2006-09-26 2010-02-18 ケース ウエスタン リザーブ ユニバーシティ サイトカインシグナリング
WO2009117706A2 (en) 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Also Published As

Publication number Publication date
EP2485723B1 (en) 2013-12-11
SMT201400033B (it) 2014-07-07
BR112012007991A2 (pt) 2017-07-25
EA201270513A1 (ru) 2012-11-30
MX2012004082A (es) 2012-07-25
EA021298B1 (ru) 2015-05-29
DK2485723T3 (en) 2014-03-17
US20120202884A1 (en) 2012-08-09
RS53249B (sr) 2014-08-29
KR101817912B1 (ko) 2018-02-21
KR101759362B1 (ko) 2017-07-18
JP2015145404A (ja) 2015-08-13
CY1115018T1 (el) 2017-01-25
JP2013506704A (ja) 2013-02-28
SI2485723T1 (sl) 2014-06-30
EP2308484A1 (en) 2011-04-13
EP2485723A1 (en) 2012-08-15
ME01719B (me) 2014-09-20
CN102665703A (zh) 2012-09-12
CN102665703B (zh) 2016-04-20
AU2010305385B2 (en) 2016-04-21
JP6097328B2 (ja) 2017-03-15
HRP20140202T1 (en) 2014-05-23
BR112012007991B8 (pt) 2021-05-25
AU2010305385A1 (en) 2012-04-26
NZ599172A (en) 2014-03-28
BR112012007991B1 (pt) 2020-12-15
PT2485723E (pt) 2014-03-13
CN104906572A (zh) 2015-09-16
CA2775902A1 (en) 2011-04-14
IL219037A (en) 2015-01-29
IL219037A0 (en) 2012-06-28
JP5834010B2 (ja) 2015-12-16
CA2775902C (en) 2016-11-29
ES2451349T3 (es) 2014-03-26
KR20120083440A (ko) 2012-07-25
HK1175993A1 (zh) 2013-07-19
KR20170068625A (ko) 2017-06-19
PL2485723T3 (pl) 2014-07-31
WO2011042466A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
KR101650264B1 (ko) 보체 활성을 저해함으로써 동종이식편의 생존 연장
HK1213777A1 (zh) 在胰岛移植中作为佐剂的cxcr1/2抑制剂
AU2018201965B2 (en) CTLA4 fusion proteins for the treatment of diabetes
US20060211725A1 (en) Use
EP1429845B1 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
Waegell et al. A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection
AU2010305384B2 (en) Sulfonamides for the prevention of diabetes
US11969397B2 (en) Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor
HK1175993B (en) Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
Gabardi et al. Immunosuppressive Pharmacotherapy
HK1174557B (en) Sulfonamides for the prevention of diabetes